Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGENGet Rating) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.

Oragenics Price Performance

Shares of NYSE:OGEN opened at $0.20 on Monday. The firm has a market capitalization of $23.46 million, a PE ratio of -1.54 and a beta of 0.24. The business has a 50-day moving average of $0.23 and a two-hundred day moving average of $0.29. Oragenics has a 12 month low of $0.19 and a 12 month high of $0.63.

Oragenics Company Profile

(Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Articles

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.